Oregovomab: an investigational agent for the treatment of advanced ovarian cancer

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
   PubMed Web of Science ®Google Scholar
• Gupta D, Lis CG. Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature. J Ovarian Res. 2009;2:13.
   PubMed Web of Science ®Google Scholar
• Berek JS, Taylor PT, Nicodemus CF. CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. J Immunother. 2008;31:207–214.
   PubMed Web of Science ®Google Scholar
• Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 2011;61:183–203.
   PubMed Web of Science ®Google Scholar
• Colombo PE, Fabbro M, Theillet C, et al. Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer. Crit Rev Oncol Hematol. 2014;89:207–216.
   PubMed Web of Science ®Google Scholar
• Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473–2483.
   PubMed Web of Science ®Google Scholar
• Oza AM, Cook AD, Pfisterer J, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16:928–936.
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30:2039–2045.
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32:1302–1308.
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1274–1284.
   PubMed Web of Science ®Google Scholar
• Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375:2154–2164.
   PubMed Web of Science ®Google Scholar
• Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:1949–1961.
   PubMed Web of Science ®Google Scholar
• Poveda A, Floquette A, Ledermann JA, et al. T. Final overall survival results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation. J Clin Oncol. 2020;38(15_suppl):6002.
   Web of Science ®Google Scholar
• Veliparib in treating patients with malignant solid tumors that do not respond to previous therapy. Available from: https://clinicaltrials.gov/ct2/show/NCT00892736
   Google Scholar
• Veliparib monotherapy for relapsed ovarian cancer with BRCA mutation (Veli-BRCA). Available from: https://clinicaltrials.gov/ct2/show/NCT01472783
   Google Scholar
• Veliparib in treating patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT01540565
   Google Scholar
• Mirza MR, Avall Lundqvist E, Birrer MJ, et al. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. Lancet Oncol. 2019;20:1409–1419.
   PubMed Web of Science ®Google Scholar
• Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379:2495–2505.
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381:2416–2428.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Martin A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381:2391–2402.
   PubMed Web of Science ®Google Scholar
• Coleman RL, Fleming GF, Brady MF, et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med. 2019;381:2403–2415.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30.
   PubMed Web of Science ®Google Scholar
• Ledermann JA, Colombo N, Oza A et al. Avelumab in combination with and/or following chemotherapy vs chemotherapy alone in patients with previously untreated epithelial ovarian cancer: results from the phase 3 javelin ovarian 100 trial. Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, Toronto, Canada; 2020; LBA 25 - Scientific Plenary.
   Google Scholar
• Li A, Yi M, Qin S, et al. Prospects for combining immune checkpoint blockade with PARP inhibition. J Hematol Oncol. 2019;12:98.
   PubMed Web of Science ®Google Scholar
• Javelin parp medley: avelumab plus talazoparib in locally advanced or metastatic solid tumors. Available from: https://clinicaltrials.gov/ct2/show/NCT03330405
   Google Scholar
• Moore KN, Pignata S. Trials in progress: iMagyn050/GOG 3015/ENGOT-OV39. A Phase III, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer. Int J Gynecol Cancer. 2019;29:430–433.
   Web of Science ®Google Scholar
• Weiner LM, Dhodapkar MV, Ferrone S. Monoclonal antibodies for cancer immunotherapy. Lancet. 2009;373:1033–1040.
   PubMed Web of Science ®Google Scholar
• Sabbatini P, Harter P, Scambia G, et al. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO–the MIMOSA study. J Clin Oncol. 2013;31:1554–1561.
   PubMed Web of Science ®Google Scholar
• Ventriglia J, Paciolla I, Pisano C, et al. Immunotherapy in ovarian, endometrial and cervical cancer: state of the art and future perspectives. Cancer Treat Rev. 2017;59:109–116.
   PubMed Web of Science ®Google Scholar
• Noujaim AA, Schultes BC, Baum RP, et al. Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13–evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo. Cancer Biother Radiopharm. 2001;16:187–203.
   PubMed Web of Science ®Google Scholar
• Schultes BC, Baum RP, Niesen A, et al. Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1). Cancer Immunol Immunother. 1998;46:201–212.
   PubMed Web of Science ®Google Scholar
• Mobus VJ, Baum RP, Bolle M, et al. Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. Am J Obstet Gynecol. 2003;189:28–36.
   PubMed Web of Science ®Google Scholar
• Levin JL, Kavanagh JJ, Nicodemus CF, et al. Immunologic and pharmacokinetic comparability profiles of Orarex(MAb B43.13) in women with ovarian cancer. Proc Am Assoc Cancer Res. 2003;44(2):767,abstract 3851.
   Google Scholar
• Baum RP, Noujaim AA, Nanci A, et al. Clinical course of ovarian cancer patients under repeated stimulation of HAMA using MAb OC125 and B43.13. Hybridoma. 1993;12:583–589.
   PubMed Web of Science ®Google Scholar
• Berek JS, Taylor PT, Gordon A, et al. Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol. 2004;22:3507–3516.
   PubMed Web of Science ®Google Scholar
• Braly P, Nicodemus CF, Chu C, et al. The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer. J Immunother. 2009;32:54–65.
   PubMed Web of Science ®Google Scholar
• Brewer M, Angioli R, Scambia G, et al. Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study. Gynecol Oncol. 2020;156:523–529.
   PubMed Web of Science ®Google Scholar
• Battaglia A, Buzzonetti A, Fossati M, et al. Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients. Cancer Immunol Immunother. 2020;69:383–397.
   PubMed Web of Science ®Google Scholar
• Gordon AN, Schultes BC, Gallion H, et al. CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients. Gynecol Oncol. 2004;94:340–351.
   PubMed Web of Science ®Google Scholar
• Ehlen TG, Hoskins PJ, Miller D, et al. A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. Int J Gynecol Cancer. 2005;15:1023–1034.
   PubMed Web of Science ®Google Scholar
• Berek J, Taylor P, McGuire W, et al. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol. 2009;27:418–425.
   PubMed Web of Science ®Google Scholar
• Oregovomab plus chemo in newly diagnosed patients with advanced epithelial ovarian cancer following optimal debulking surgery (FLORA-5). Available from: https://clinicaltrials.gov/ct2/show/NCT04498117?term=Flora-5&draw=2&rank=1
   Google Scholar
• Pietragalla A, Minucci A, Marchetti C, et al. Can somatic BRCA2 status solve a case of olaparib monotherapy resistance? Int J Gynecol Cancer. 2019;29:1440–1445.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609–615.
   PubMed Web of Science ®Google Scholar
• Phase Ib/IIa trial to evaluate oregovomab and nivolumab in epithelial cancer of ovarian, tubal or peritoneal origin (ORION-01). Available from: https://clinicaltrials.gov/ct2/show/NCT03100006
   Google Scholar
• The safety and antitumor activity of the combination of oregovomab and hiltonol in recurrent advanced ovarian cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT03162562
   Google Scholar